abstract
OBJECTIVE:
Women
with primary
platinum resistant (PPR) high grade serous ovarian cancer
(HGSOC) are known to have a poor prognosis. Less is known regarding
outcomes in patients with
acquired platinum resistance (APR). The goal
of this study was to evaluate survival in both PPR and APR patients.
METHODS:
A
retrospective review of HGSOC patients diagnosed between 2000 and 2010
was performed. Descriptive statistics summarized clinical
characteristics and demographics. The Kaplan-Meier method estimated
progression free survival (PFS) and overall survival (OS). The
association of OS and clinical factors was modeled using Cox
proportional-hazards.
CONCLUSIONS:
Platinum
resistance confers a poor prognosis in the APR and PPR setting. The
number of biologic agents received is the strongest predictor of OS
among women with PPR. Cancer stage and clinical trial participation
predicts OS in patients with APR. Providing opportunities to participate
in clinical trials, especially those involving targeted therapy, should
be a priority in these populations.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.